PubMed Health⌕ Search

Biomedical subjects

X X Fu

Publications and source records attributed to X X Fu.

15 recordsLinked to original sources
PubMed2000

A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.

BACKGROUND: Alpha-interferons are the accepted therapy for patients infected with chronic hepatitis C virus (HCV) in China. However, consensus interferon (CIFN) for HCV treatment is effective in patients with chronic hepatitis C from Western countries. METHODS: This randomized, controlled trial was conducted to determine the safety and efficacy of CIFN at two doses, and to compare it with alpha-2a-interferon (IFN-alpha-2a) in Chinese patients with chronic HCV. Interferon-naive patients with chronic HCV infection (n = 187) were randomly chosen to receive 15 microg CIFN or 9 microg or 3 MU IFN-alpha-2a subcutaneously, three times a week for 24 weeks, followed by a 24 week observation period. Efficacy was evaluated by the normalization of serum alanine aminotransferase (ALT) and the non-detectability disappearance of serum HCV-RNA by using reverse-transcription-polymerase chain reaction. The safety of CIFN was evaluated by recording the type and severity of adverse effects. RESULTS: The combined ALT and HCV-RNA end-of-treatment and sustained responses were observed to be greater for treatment with 15 microg CIFN (59.0% and 55.7%, respectively) compared to IFN alpha-2a (36.1% and 39.3%, respectively; P = 0.01 for the end-of-treatment, P = 0.07 for the sustained response). The combined ALT and HCV-RNA end-of-treatment and sustained responses for treatment with 9 microg CIFN (both 49.2%) were higher than those for IFN-alpha-2a (not statistically significant). Data were analyzed by using a logistic-multiple-variate regression model, which indicated that the higher IFN dose (15 microg or 9 microg CIFN vs 3 MU IFN-alpha-2a; P < 0.01) appeared to be associated with a better sustained response. The type, frequency and severity of adverse effects were comparable across treatment groups. CONCLUSIONS: Consensus interferon appears to be safe and effective at concentrations of 9 and 15 microg, but 15 microg CIFN may be more effective than 3 MU IFN-alpha-2a, without increased toxicity.

Adolescent↗
PubMed1996

[Inhibitory effects of co-cinobufotalin oral liquor on hepatitis B in vitro].

Co-Cinobufotalin Oral Liquor (CCOL) was studied for its ability to inhibit hepatitis B virus DNA replication, HBsAg and HBeAg expression in a HBV-transfected cell line (2.2.15 cell). The result showed that ID50 (the drug concentration that inhibits HBsAg or HBeAg secretion by 50%) was 0.08 mg/ml and 0.07 mg/ml on HBsAg and HBeAg respectively. CD50 (the drug concentration that reduces cell growth by 50%) was 2.5 mg/ml. TI (therapeutic index) was 31.3 and 35.7 respectively. The present data suggest that CCOL could exert a potent antiviral activity against HBV in vitro. Southern blot showed that CCOL inhibited HBV-DNA repication in a dose-dependent manner.

Antiviral Agents↗
PubMed1994

[The diagnostic value of anti-HCV test in HCV infection].

Two hundred and ninety-six samples of patient serum and 28 samples of donor serum were tested for anti-HCV with second generation domestic made testing kit, and for HCV RNA with PCR assay. The aim of this study is to assess the diagnostic value of anti-HCV test in HCV infection and to discuss its value in screening of donors. The results were as follows HCV RNA was detected in 81.6% of the anti-HCV positive patient samples and in 21.7% of the anti-HCV negative patient samples. HCV RNA was not detected in 28 anti-HCV negative donors. These results reveals that positive anti-HCV is of high diagnostic value in HCV infection. Anti-HCV negative could not exclude HCV infection for samples suspected of HCV infection. However, screening donors with anti-HCV probably decreases HCV RNA positive rate considerably.

Blood Donors↗
PubMed1994

[Detection of plus and minus strand hepatitis C virus RNA in peripheral blood mononuclear cells and spermatid].

Plus and minus strands of HCV RNA in plasma, peripheral blood mononuclear cells (PBMC), sperm and spermatid of 8 patients with chronic hepatitis C were tested by the method of PCR to find out whether HCV exists and duplicates in extrahepatic cells or not. Plus HCV RNA was detected in all the plasma samples, but no minus HCV RNA was detected. Plus strand HCV RNA was detected in 5 of 8 PBMC samples and minus strand in 2 of the 5 samples. Three of 5 male chronic hepatitis C patients were willing to cooperate and offer their sperm for detection. In the patients, no minus but plus strand HCV RNA was detected in both supernatant of sperm and spermatid. HCV RNA was not detected in the last washing solution for spermatid. The results suggest that: (1). Probably, only plus HCV RNA exists in plasma; (2). HCV exists and probably duplicates in PBMC; (3). HCV exists in sperm. The possibility of transmission of hepatitis C by sexual intercourse is really existent. But, HCV probably don't duplicate in spermatid.

Adult↗
PubMed1994

[Preliminary studies on inactivation of serum HCV].

Effects of heating and 60cobalt (60Co) irradiation to hepatitis C virus (HCV) RNA in sera were studied. HCV-RNA can not be detected by PCR in 10 positive serum samples after being heated at 56 degrees C for 10 hours. Whereas, HCV-RNA can still be detected in positive sera after being lyophilized and then heated at 60 degrees C for 20 hours. It suggested heating at 56 degrees C for 10 hours can inactivate HCV in sera and the sera should be in liquid status when thermal inactivation is taken. Lyophilized sera with thermal inactivation for HCV should be inactivated first and then lyophilized. But the safety of sera with heat-treatment should be further investigated. Inactivation of HCV in sera with 60Co irradiation needed extra large dose of it, and protein components in sera would obviously be altered. Therefore, inactivation of HCV in sera with 60Co irradiation is impractical.

Base Sequence↗
PubMed1991

[Therapeutic effect of combined treatment with Ara-A dauricine and Chinese herbs in chronic hepatitis B infection].

77 patients with chronic active or persistent hepatitis of type B proved by liver biopsy were divided into two groups. 39 cases were treated with Ara-A. dauricine and polysaccharide of pore umbellate as group I. 38 cases were treated with Ara-A, radix isatidis and radix salviae mitiorrhize as group II. By the end of 3 months in the course, the effective rates of ALT and AST were 68.6% and 68.4% in group I, 34.4% and 34.8% in group II. The rates of HBeAg from positive to negative were 35.9% and 39.5% in group I and II respectively. Follow up to 3 months after cessation of therapy, ALT level was normal in 55.6% of group I and 60% of group II: HBeAg was negative in 42.9% of group I and in 50% of group II. Follow up to 9 months after cessation of the treatment, ALT was normal in 56.3% of group I and in 62.5% of group II, HBeAg was negative in 37.5% of group I and in 60% of group II. These results show that dauricine and polysaccharide of pore umbellate did not strengthen the antiviral effect of Ara-A.

Adolescent↗
PubMed1988

Insulinlike growth factor II expression and oval cell proliferation associated with hepatocarcinogenesis in woodchuck hepatitis virus carriers.

Insulinlike growth factor II (IGF-II) is a highly mitogenic fetal growth factor suspected of regulating the growth of a wide spectrum of tissues via an autocrine or paracrine mode of action or both. High steady-state levels of IGF-II RNA were detected in 45% of hepatocellular carcinomas (HCCs) arising from woodchuck livers with persistent woodchuck hepatitis virus (WHV) infection. Analysis of WHV RNA in the same HCCs revealed that HCCs with high levels of IGF-II RNA contained low or undetectable levels of WHV RNA and HCCs with low levels of IGF-II RNA contained high levels of WHV RNA. Integrated WHV DNA was present in HCCs from both groups, but viral DNA replicating forms were present, predominantly in HCCs with low levels of IGF-II. Several IGF-II RNAs, the most prominent of which were poly(A) species of approximately 3.75 and 1.1 to 1.3 kilobases, were detected only in precancerous nodules and HCCs. Levels of IGF-II were elevated two- to three-fold in the serum of woodchucks with chronic active hepatitis preceding the occurrence of HCC. Proliferation of a population of oval cells, which arise from portal tract regions in the liver, preceded the development of HCC and was a prominent feature of livers from which tumors with high levels of IGF-II occurred. The HCCs tended to have distinct histological features according to their growth factor status. Tumors with low levels of IGF-II were generally highly differentiated acinar-trabecular HCCs, whereas tumors with high levels of IGF-II were more anaplastic, with regions of fibrosis and fatty accumulation. A model to relate the pathology of WHV infection to oval cell proliferation and IGF-II expression in the development of these heterogeneous HCCs is presented.

Animals↗